Phytopharm PLC (PYM.L)
1.33GBp
29 Apr 2013
0.18p (+15.22%)
1.15p
1.15p
1.33p
1.16p
1,428,870
1,349,929
12.98p
1.02p
PYM.L
About
Overall
| Beta: | 0.71 |
| Market Cap (Mil.): | £4.60 |
| Shares Outstanding (Mil.): | 346.90 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| PYM.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 54.65 | 35.85 |
| EPS (TTM): | -0.02 | -- | -- |
| ROI: | -63.82 | 0.83 | 18.76 |
| ROE: | -63.82 | 1.79 | 19.57 |
Phytopharm gives up after Parkinson's drug failure
LONDON - British biotech Phytopharm gave up its search for a treatment for Parkinson's Disease using a drug derived from subtropical plants on Tuesday and said it was looking to sell the business.
UPDATE 1-Phytopharm gives up after Parkinson's drug failure
LONDON, March 26 - British biotech Phytopharm gave up its search for a treatment for Parkinson's Disease using a drug derived from subtropical plants on Tuesday and said it was looking to sell the business.
BRIEF-Phytopharm stopping R&D spend, cutting headcount
LONDON, March 26 - Phytopharm PLC : * Strategic review update * No further research and development expenditure will be committed, staff
Phytopharm hit by failure of Parkinson's drug
LONDON - Phytopharm said its major drug hope for treating Parkinson's disease had failed in a clinical trial, the latest British biotech company to disappoint after showing early promise.
UPDATE 1-Phytopharm hit by failure of Parkinson's drug
* Phytopharm's shares fall more than 80 pct (Adds details, analyst reaction, shares)
BRIEF-Phytopharm Parkinson's trial shows no benefit
LONDON, Feb 18 - Phytopharm PLC : * Results from Cogane (TM) in parkinson's disease clinical trial * Headline results indicated that cogane had no beneficial effects on patients'
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
